CanBas Co., Ltd. Share Price

Equities

4575

JP3244570002

Pharmaceuticals

Market Closed - Japan Exchange 07:00:00 19/07/2024 BST 5-day change 1st Jan Change
673 JPY -4.81% Intraday chart for CanBas Co., Ltd. +12.17% -29.90%

Financials

Sales 2022 - Sales 2023 - Capitalization 20.13B 128M 9.9B
Net income 2022 -855M -5.42M -420M Net income 2023 -1.24B -7.89M -612M EV / Sales 2022 -
Net cash position 2022 370M 2.35M 182M Net cash position 2023 1.62B 10.26M 795M EV / Sales 2023 -
P/E ratio 2022
-7.35 x
P/E ratio 2023
-14.8 x
Employees 12
Yield 2022 *
-
Yield 2023
-
Free-Float 96.85%
More Fundamentals * Estimated data
Dynamic Chart
CanBas Co., Ltd.(TSE:4575) added to S&P Global BMI Index CI
CanBas Co., Ltd. announced that it has received ¥748.0425 million in funding CI
CanBas Co., Ltd. announced that it expects to receive ¥748.0425 million in funding CI
CanBas Co., Ltd. announced that it has received ¥16.38843 million in funding from Inflexion Partners, and another investor CI
CanBas Co., Ltd. announced that it expects to receive ¥16.38843 million in funding CI
CanBas Co., Ltd. announced that it expects to receive ¥9.678321 million in funding from Advantage Partners, Inc. and other investors CI
CanBas Co., Ltd. announced that it has received ¥754.278462 million in funding CI
CanBas Co., Ltd. announced that it expects to receive ¥754.278462 million in funding CI
CanBas Co., Ltd. announced that it has received ¥210.17 million in funding from Milestone Capital Management Co., Ltd. CI
CanBas Co., Ltd. announced that it expects to receive ¥209.2 million in funding from Milestone Capital Management Co., Ltd. CI
CanBas Co., Ltd. Enters into Research Agreement with Fujifilm Corp CI
CanBas Co., Ltd. announced that it has received ¥7.15 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm. CI
CanBas Co., Ltd. announced that it expects to receive ¥7.15 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm. CI
Stemline Therapeutics, Inc. Announces Exclusive License from Canbas Co., Ltd CI
CanBas Co., Ltd. announced that it has received ¥109.66 million in funding from Milestone Capital Management Co., Ltd. CI
More news
1 day-4.81%
1 week+12.17%
Current month+23.94%
1 month+41.98%
3 months+50.90%
6 months-28.02%
Current year-29.90%
More quotes
1 week
596.00
Extreme 596
800.00
1 month
468.00
Extreme 468
800.00
Current year
411.00
Extreme 411
1 039.00
1 year
411.00
Extreme 411
1 136.00
3 years
162.00
Extreme 162
2 975.00
5 years
162.00
Extreme 162
2 975.00
10 years
162.00
Extreme 162
2 975.00
More quotes
Managers TitleAgeSince
Founder 66 17/01/00
Director of Finance/CFO 60 31/08/00
Chief Administrative Officer 61 30/11/08
Members of the board TitleAgeSince
Founder 66 17/01/00
Director of Finance/CFO 60 31/08/00
Director/Board Member 74 31/08/03
More insiders
Date Price Change Volume
19/07/24 673 -4.81% 668,700
18/07/24 707 -1.81% 1,813,000
17/07/24 720 +13.74% 2,069,400
16/07/24 633 +5.50% 379,500
12/07/24 600 +1.52% 654,000

Delayed Quote Japan Exchange, July 19, 2024 at 07:00 am

More quotes
CanBas Co Ltd is a Japan-based company mainly engaged in drug development and research. The company is mainly engaged in the basic anticancer drug discovery research (including development of drug discovery concepts, selection of drug candidate compounds using methods based on these concept developments, simple animal studies, and collection and analysis of basic data on anticancer drug candidates that have entered development) and early clinical development (including preclinical studies prior to submission of applications to start clinical trials and the first part of clinical trials).
Calendar
More about the company